Overexpression of HGF/SF and Met in breast carcinoma [8]–[10] correlates with triple-negative and basal type tumors [11], [12], and are strong independent predictors of decreased survival [9], [13]–[15], including stage-I patients [16]–[19]. The gene discussed is MET; the disease is breast carcinoma.